Dr. Mikhail Kosiborod reviewed research at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease on the cardiovascular benefits of Ozempic/Wegovy for adults with obesity.
One Saint Luke’s East patient took time on Christmas Eve to show appreciation for nurses and other health care workers who are spending the holidays at the hospital caring for others.
What do I do if I’m exposed? How can I stay safe while traveling? What’s the difference between COVID and the flu? Dr. Sarah Boyd, infectious disease physician at Saint Luke's Health System, answers.
The study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity.
A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.
Mental health can play a big role in setting yourself up for success when it comes to setting New Year’s resolutions and making healthy lifestyle changes.
